慢性阻塞性肺病急性加重期抗凝治疗的临床观察  

Observation on the efficacy of anticoagulation in patients with acute exacerbation of chronic obstructive pulmonary disease

作　　者：张春美[1] 

机构地区：[1]安徽省合肥市第一人民医院呼吸内科,安徽合肥230061

出　　处：《现代预防医学》2012年第22期6075-6076,6081,共3页Modern Preventive Medicine

摘　　要：目的观察低分子肝素治疗在慢性阻塞性肺疾病急性加重期(AECOPD)的作用及疗效。方法将90例AE-COPD患者随机分为治疗组(A组)48例和对照组(B组)42例。对照组予以常规治疗,治疗组在常规治疗基础上加用低分子肝素抗凝治疗,7d为一疗程。结果治疗组较对照组动脉血氧分压和二氧化碳分压明显好转,D-二聚体明显下降(P﹤0.05),呼吸困难改善明显,住院时间缩短,总有效率(显效+有效)(93.8%)高于对照组(88.1%),无严重不良反应发生。结论低分子肝素抗凝治疗能改善AECOPD患者血液高凝状态,利于病情改善。OBJECTIVE To investigate the efficacy of anticoagulation in patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD).METHODS 90 patients with AECOPD were randomized to the anticoagulation group(n = 48)and the control group(n = 42).Low-molecular weight heparin was administrated for 7 days in the anticoagulation group in addition to regular therapies.RESULTS Compared with the control group,the PaO2 and PaCO2 levels and dyspnea indices significantly improved in anticoagulation group,D-dimer level and length-of-stay significantly reduced,and the effective rate was significantly increased(93.8% vs 88.1%).No significant adverse effects were observed as a result of anticoagulation therapy.CONCLUSION Low-molecular weight heparin is effective in improving the hypercoagulative state in patients with AECOPD,which ameliorates their clinical status.

关 键 词：低分子肝素 抗凝治疗 慢性阻塞性肺病 急性加重期 

分 类 号：R563.9[医药卫生—呼吸系统]